Antipsychotic Drugs

Correct Answer

C — Clozapine

Rationale

Clozapine is the only antipsychotic with a Food and Drug Administration indication specifically for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. This indication is supported by a large international trial demonstrating reduced suicidality compared with olanzapine. No other antipsychotic — including olanzapine, quetiapine, or risperidone — carries this specific regulatory designation. Clozapine also holds the distinction of being the only antipsychotic with demonstrated superior efficacy in treatment-resistant schizophrenia.

Correct Answer

A — Paliperidone

Rationale

Paliperidone (9-hydroxyrisperidone) is the active metabolite of risperidone — produced when risperidone is converted by the cytochrome P450 2D6 enzyme — and is itself approved as an independent antipsychotic agent with its own formulations and dosing regimens. Quetiapine, aripiprazole, and olanzapine are pharmacologically distinct agents that are not metabolites of other approved antipsychotics. The risperidone-paliperidone relationship is the primary parent drug-to-active-metabolite pair in the antipsychotic class.

Correct Answer

D — Quetiapine

Rationale

Quetiapine (as quetiapine extended-release) has Food and Drug Administration approval for the treatment of bipolar depression — one of the most difficult phases of bipolar disorder to treat pharmacologically. This indication is supported by large randomized trials demonstrating superiority over placebo on depressive rating scales. Quetiapine's broad approved indication range also includes schizophrenia, bipolar mania, and adjunctive therapy in major depressive disorder. Risperidone is approved for schizophrenia and bipolar mania. Olanzapine is approved for schizophrenia and bipolar mania; bipolar depression only in fixed combination with fluoxetine. Clozapine is approved for treatment-resistant schizophrenia and suicidality reduction — not bipolar depression.

Correct Answer

B — Risperidone

Rationale

Risperidone is primarily metabolized by cytochrome P450 2D6, which converts it to its active metabolite paliperidone. This metabolic pathway makes risperidone sensitive to strong cytochrome P450 2D6 inhibitors — such as fluoxetine, paroxetine, and bupropion — which impair the conversion and raise risperidone plasma levels, requiring dose reduction. Quetiapine is primarily metabolized by cytochrome P450 3A4. Olanzapine and clozapine are primarily metabolized by cytochrome P450 1A2 and are therefore sensitive to the enzyme-inducing effects of cigarette smoking.

Correct Answer

C — Valproate

Rationale

Valproate is classified as the preferred antiseizure drug when co-administration with clozapine is required for seizure management. Carbamazepine is contraindicated with clozapine — it is a potent cytochrome P450 1A2 inducer that substantially reduces clozapine plasma levels and independently adds bone marrow suppression risk, making the combination pharmacologically hazardous. Phenytoin and lamotrigine have not been identified as preferred agents in this specific co-prescribing role. Clozapine's dose-dependent seizure risk reaches approximately 5 percent at doses above 600 milligrams per day, making antiseizure drug co-prescribing a clinically relevant consideration for patients requiring high clozapine doses.

Correct Answer

A — Metformin

Rationale

Metformin has the strongest evidence base as a pharmacological adjunct for antipsychotic-induced weight gain, producing mean weight reductions of 2 to 3 kilograms and improvements in insulin sensitivity in randomized trials. It is particularly relevant for patients on olanzapine or clozapine, the agents with the highest metabolic burden in the antipsychotic class. Orlistat, naltrexone, and topiramate have been studied in this context but have a weaker evidence base than metformin and are not identified as the preferred first-line adjunct in this specific setting. Switching to a more metabolically favorable antipsychotic — such as aripiprazole, lurasidone, or ziprasidone — remains the most effective long-term metabolic strategy when clinically feasible.

Correct Answer

D — Weekly for the first 6 months, then every two weeks for months 6 to 12, then monthly thereafter

Rationale

The Clozapine Risk Evaluation and Mitigation Strategy program requires absolute neutrophil count monitoring weekly for the first 6 months of therapy — the period of highest agranulocytosis risk — then every two weeks for months 6 to 12, and monthly thereafter for as long as the patient continues clozapine. The drug is dispensed only when the count is confirmed adequate. Clozapine causes agranulocytosis in approximately 0.8 to 1 percent of patients; the condition is idiosyncratic and not dose-dependent, making regular monitoring essential regardless of clinical stability. Because agranulocytosis is almost always caught before it becomes life-threatening under this protocol, the mandatory monitoring system transforms a potentially fatal adverse effect into a manageable one. The monitoring schedule reflects declining risk over time but never reaches a point where monitoring is discontinued entirely while the patient remains on clozapine.

Correct Answer

B — Clozapine acts as an agonist at muscarinic M4 receptors in the salivary glands, directly stimulating salivation despite blocking M1 receptors elsewhere

Rationale

Clozapine's receptor profile is unusually complex, and sialorrhea illustrates this complexity. Although clozapine blocks muscarinic M1 receptors throughout the body — producing the expected anticholinergic effects of dry mouth, urinary retention, and constipation in many patients — it simultaneously acts as an agonist at muscarinic M4 receptors in the salivary glands. M4 agonism directly stimulates salivary secretion, producing excessive drooling that is particularly troublesome at night. This paradoxical pro-secretory effect occurs despite the concurrent M1 blockade, because M4 and M1 receptors subserve different functions in salivary tissue. Management includes sublingual atropine drops or glycopyrrolate to reduce salivary output through selective muscarinic blockade.

Correct Answer

A — Histamine H1 blockade stimulates appetite and reduces energy expenditure, while serotonin 5-HT2C blockade impairs hypothalamic satiety signaling

Rationale

Olanzapine's pronounced metabolic liability arises from two converging receptor mechanisms. First, blockade of histamine H1 receptors in the hypothalamus stimulates appetite and reduces energy expenditure — the same mechanism responsible for sedation and weight gain with first-generation antihistamines. Second, blockade of serotonin 5-HT2C receptors in the hypothalamus impairs satiety signaling, reducing the sensation of fullness after eating and promoting continued caloric intake. These two effects are additive: H1 blockade drives hunger up while 5-HT2C blockade prevents satiety from providing a stop signal. Together they produce the substantial weight gain that distinguishes olanzapine and clozapine from other antipsychotics. The 5-HT2A receptor — responsible for the atypicality mechanism that reduces extrapyramidal symptoms — is distinct from 5-HT2C and does not drive weight gain through the same pathway.

Correct Answer

C — Intramuscular olanzapine must never be co-administered with intramuscular or intravenous benzodiazepines in the same session due to risk of severe respiratory depression and death

Rationale

The combination of intramuscular olanzapine with intramuscular or intravenous benzodiazepines in the same clinical session is an absolute contraindication. Cases of severe respiratory depression and death have been specifically attributed to this combination — the pharmacodynamic interaction produces additive central nervous system and respiratory depression that exceeds what either agent produces alone. This restriction applies regardless of the clinical urgency of sedation; when a benzodiazepine is necessary alongside an antipsychotic for acute agitation, a different antipsychotic such as haloperidol must be used. This safety rule is specific to intramuscular olanzapine and does not apply to the oral formulation in the same way. Absolute neutrophil count monitoring is required for clozapine, not olanzapine. Baseline electrocardiogram requirements apply specifically to intramuscular ziprasidone and agents with significant QTc risk.

Correct Answer

D — Quetiapine dissociates rapidly from D2 receptors, so D2 occupancy peaks transiently after each dose and falls quickly, preventing the sustained nigrostriatal blockade that drives extrapyramidal symptoms and hyperprolactinemia

Rationale

Quetiapine has low D2 receptor affinity and dissociates from D2 receptors unusually rapidly — a property sometimes called fast-off kinetics. After each dose, D2 occupancy rises transiently to the therapeutic range during peak plasma levels, then falls substantially within hours as quetiapine dissociates. This transient pattern means that sustained nigrostriatal D2 blockade — the pharmacological driver of extrapyramidal symptoms — never accumulates. Similarly, tuberoinfundibular D2 occupancy is insufficient and too brief to produce persistent prolactin elevation. This mechanism is pharmacologically distinct from the 5-HT2A to D2 ratio concept that explains reduced extrapyramidal symptoms for other second-generation antipsychotics: quetiapine's advantage comes from receptor kinetics, not from 5-HT2A offset. Quetiapine does not achieve pathway-selective D2 blockade — it blocks D2 receptors throughout the brain, just transiently.

Correct Answer

B — Quetiapine levels rise approximately fivefold due to impaired hepatic metabolism, requiring dose reduction to approximately one-sixth of the standard dose

Rationale

Because quetiapine depends exclusively on cytochrome P450 3A4 for its hepatic metabolism, strong inhibitors of this enzyme — including azole antifungals such as fluconazole and ketoconazole, as well as clarithromycin and ritonavir — dramatically reduce quetiapine clearance. Plasma levels can rise approximately fivefold on the same oral dose, producing toxicity including excessive sedation, orthostatic hypotension, and metabolic adverse effects. When such a combination cannot be avoided, the quetiapine dose must be reduced to approximately one-sixth of the standard dose during co-administration and then restored when the inhibitor is discontinued. The converse interaction — with strong inducers such as carbamazepine or rifampin — reduces quetiapine levels by up to 90 percent, potentially rendering standard doses subtherapeutic. These large-magnitude interactions make cytochrome P450 3A4 status a primary consideration whenever any new medication is added to quetiapine therapy.

Correct Answer

A — At doses above approximately 8 milligrams per day, dopamine D2 occupancy crosses the threshold at which extrapyramidal symptoms emerge, and risperidone's serotonin 5-HT2A to D2 ratio no longer provides adequate protection against nigrostriatal motor effects

Rationale

Risperidone has high affinity for both dopamine D2 and serotonin 5-HT2A receptors. At doses at or below approximately 6 milligrams per day, the 5-HT2A to D2 ratio is favorable — serotonin 5-HT2A blockade provides sufficient dopamine disinhibition in the nigrostriatal pathway to keep extrapyramidal symptom rates low, comparable to other second-generation antipsychotics. At doses above 8 milligrams per day, D2 occupancy rises to the range where nigrostriatal blockade becomes dominant and the protective effect of 5-HT2A blockade is overwhelmed. Unlike olanzapine or quetiapine, risperidone lacks meaningful histamine H1 or anticholinergic activity to provide additional buffering of this motor effect. The practical implication is that risperidone doses above 6 milligrams per day offer diminishing antipsychotic benefit at the cost of increasing extrapyramidal symptom rates — dose optimization is particularly important with this agent.

Correct Answer

C — Paliperidone undergoes minimal hepatic metabolism and is eliminated primarily unchanged in the urine, making its plasma levels largely unaffected by cytochrome P450 enzyme inhibitors

Rationale

Paliperidone is the active metabolite of risperidone and shares its receptor pharmacology, but differs substantially in its pharmacokinetics. Approximately 59 percent of a paliperidone dose is excreted unchanged in the urine, making paliperidone the notable exception among antipsychotics in its independence from hepatic cytochrome P450 enzymes. Strong cytochrome P450 2D6 inhibitors such as paroxetine — which substantially impair risperidone's conversion to paliperidone and raise risperidone levels — have negligible effects on paliperidone plasma concentrations. This pharmacokinetic predictability makes paliperidone the preferred agent when strong cytochrome P450 2D6 inhibitors must be co-prescribed. Paliperidone is not a prodrug requiring activation; it is itself the pharmacologically active compound. Dose adjustment in paliperidone therapy is required for renal impairment rather than hepatic impairment, reflecting its primary renal elimination route.

Correct Answer

B — Clozapine causes idiosyncratic destruction of neutrophil precursors in the bone marrow through a mechanism unrelated to its therapeutic receptor interactions

Rationale

This patient has clozapine-induced agranulocytosis — an absolute neutrophil count below 500 cells per microliter. Clozapine causes agranulocytosis in approximately 0.8 to 1 percent of patients through an idiosyncratic mechanism: it is not dose-dependent, it is not predictable from the drug's therapeutic receptor profile, and it is not related to H1 or D2 blockade. The precise mechanism involves direct toxic or immune-mediated injury to neutrophil precursors in the bone marrow. Because agranulocytosis is idiosyncratic rather than dose-dependent, reducing the clozapine dose does not reliably prevent or reverse it. The Risk Evaluation and Mitigation Strategy monitoring program exists specifically to detect this drop before it becomes life-threatening — in this case, the routine monitoring has successfully identified agranulocytosis in an asymptomatic patient at a point where intervention can prevent septic complications.

Correct Answer

D — Fluconazole inhibits cytochrome P450 3A4, impairing quetiapine metabolism and raising plasma levels approximately fivefold, producing drug excess at the previously well-tolerated dose

Rationale

Quetiapine is exclusively metabolized by cytochrome P450 3A4, and fluconazole is a potent inhibitor of this enzyme. When fluconazole is added to stable quetiapine therapy, hepatic clearance of quetiapine is substantially impaired and plasma levels rise approximately fivefold on the same dose. The patient is now experiencing the adverse effects of quetiapine excess at her previously well-tolerated dose: severe sedation from histamine H1 blockade, orthostatic hypotension and dizziness from alpha-1 adrenergic blockade, and cognitive blunting. The appropriate response is quetiapine dose reduction to approximately one-sixth of the standard dose while fluconazole is being taken, with restoration of the original dose after the antifungal course is complete. This interaction is clinically important because azole antifungals are frequently prescribed for candidal infections and the magnitude of the interaction — approximately fivefold — is sufficient to cause toxicity even from a short antifungal course.

Correct Answer

C — Blockade of histamine H1 receptors stimulates appetite and reduces energy expenditure, while blockade of serotonin 5-HT2C receptors impairs hypothalamic satiety signaling

Rationale

Olanzapine's pronounced weight gain — averaging 7 to 10 kilograms or more in the first year in susceptible patients — results from two converging receptor mechanisms. Histamine H1 blockade in the hypothalamus stimulates appetite and reduces energy expenditure, driving increased caloric intake. Serotonin 5-HT2C blockade in the hypothalamus impairs the satiety signaling that normally terminates eating, allowing continued caloric consumption beyond what the patient would otherwise seek. These two effects are additive and produce the characteristic metabolic liability that distinguishes olanzapine and clozapine from other antipsychotics. Comprehensive metabolic monitoring — weight, fasting glucose, lipid panel, and blood pressure — at baseline, 12 weeks, and annually is the standard of care for any patient on olanzapine. When significant weight gain develops, metformin has the strongest evidence base as a pharmacological adjunct when switching antipsychotics is not clinically feasible.

Correct Answer

A — Intramuscular olanzapine is absolutely contraindicated with benzodiazepines in the same session due to risk of severe respiratory depression and death — intramuscular haloperidol is an appropriate alternative

Rationale

The combination of intramuscular olanzapine with intramuscular or intravenous benzodiazepines in the same clinical session is an absolute contraindication. Cases of severe respiratory depression and death have been specifically attributed to this pharmacodynamic interaction — the additive central nervous system and respiratory depression produced by combining these agents exceeds what either produces alone. Because this patient has already received intramuscular lorazepam, intramuscular olanzapine is off the table regardless of clinical urgency. Intramuscular haloperidol is an appropriate alternative antipsychotic for acute agitation; it does not share this contraindication with benzodiazepines and is in fact commonly combined with lorazepam intramuscularly as a standard acute agitation protocol. Intramuscular ziprasidone — not olanzapine — is the agent that requires a prior electrocardiogram. Absolute neutrophil count monitoring is required for clozapine, not olanzapine.